Clinical Trial

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A（Eveotox）in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-06
notable Trial sites expanded: 2 -> 12 locations 2026-08-06
Trial Details
NCT Number NCT07242300
Lead Sponsor JHM BioPharma (Tonghua) Co. , Ltd.
Conditions Upper Limb Spasticity (ULS)
Enrollment 207 participants
Start Date 2025-12-11
Primary Completion 2026-12 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05